drugset / Trial / NCT05066230
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)
RandomizedParallel-groupTriple-blindTreatment
Summary
This Phase 3 Study will evaluate the efficacy and safety of KSI-301 in participants with moderately severe to severe non-proliferative diabetic retinopathy (NPDR).
Timeline
- Start
- 2021-09-07
- Primary completion
- 2023-08-03
- Completion
- 2023-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tarcocimab tedromer | Protein / enzyme biologic | 5 mg | Intravitreal |